203 related articles for article (PubMed ID: 34164950)
1. Current status and future readiness of Indian radiation oncologists to embrace prostate high-dose-rate brachytherapy: An Indian Brachytherapy Society survey.
Banerjee S; Sarkar S; Mahantshetty U; Shishak S; Kaliyaperumal V; Bisht SS; Gupta D; Narang K; Mayank M; Srinivasan V; Anand V; Patro KC; Prasad RR; Kataria T
J Contemp Brachytherapy; 2023 Dec; 15(6):391-398. PubMed ID: 38230402
[TBL] [Abstract][Full Text] [Related]
2. The Case for Brachytherapy: Why It Deserves a Renaissance.
Williams VM; Kahn JM; Thaker NG; Beriwal S; Nguyen PL; Arthur D; Petereit D; Dyer BA
Adv Radiat Oncol; 2021; 6(2):100605. PubMed ID: 33723523
[TBL] [Abstract][Full Text] [Related]
3. Preliminary Characterization of an Active CMOS Pad Detector for Tracking and Dosimetry in HDR Brachytherapy.
Bui TNH; Large M; Poder J; Bucci J; Bianco E; Giampaolo RA; Rivetti A; Da Rocha Rolo M; Pastuovic Z; Corradino T; Pancheri L; Petasecca M
Sensors (Basel); 2024 Jan; 24(2):. PubMed ID: 38276383
[TBL] [Abstract][Full Text] [Related]
4. Comparison of chronic gastrointestinal and genitourinary toxicities between brachytherapy and external beam radiotherapy for patients with prostate cancer: A systematic review and meta-analysis.
Li X; Shan L; Wang Q; Zhai H; Xuan Y; Yan G
Technol Health Care; 2023; 31(S1):357-372. PubMed ID: 37066936
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic Radiation Therapy versus Brachytherapy: Relative Strengths of Two Highly Efficient Options for the Treatment of Localized Prostate Cancer.
Kissel M; Créhange G; Graff P
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565355
[TBL] [Abstract][Full Text] [Related]
6. High-dose-rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome.
Strouthos I; Karagiannis E; Zamboglou N; Ferentinos K
Cancer Rep (Hoboken); 2022 Jan; 5(1):e1450. PubMed ID: 34164950
[TBL] [Abstract][Full Text] [Related]
7. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
8. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
9. Brachytherapy: current status and future strategies -- can high dose rate replace low dose rate and external beam radiotherapy?
Morton GC; Hoskin PJ
Clin Oncol (R Coll Radiol); 2013 Aug; 25(8):474-82. PubMed ID: 23727431
[TBL] [Abstract][Full Text] [Related]
10. Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer.
Strouthos I; Chatzikonstantinou G; Zamboglou N; Milickovic N; Papaioannou S; Bon D; Zamboglou C; Rödel C; Baltas D; Tselis N
Radiother Oncol; 2018 Aug; 128(2):301-307. PubMed ID: 29764692
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer.
Yoshioka Y; Yoshida K; Yamazaki H; Nonomura N; Ogawa K
J Radiat Res; 2013 Sep; 54(5):781-8. PubMed ID: 23543798
[TBL] [Abstract][Full Text] [Related]
12. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy.
Morton G; McGuffin M; Chung HT; Tseng CL; Helou J; Ravi A; Cheung P; Szumacher E; Liu S; Chu W; Zhang L; Mamedov A; Loblaw A
Radiother Oncol; 2020 May; 146():90-96. PubMed ID: 32146259
[TBL] [Abstract][Full Text] [Related]
13. Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial.
Joseph D; Denham JW; Steigler A; Lamb DS; Spry NA; Stanley J; Shannon T; Duchesne G; Atkinson C; Matthews JHL; Turner S; Kenny L; Christie D; Tai KH; Gogna NK; Kearvell R; Murray J; Ebert MA; Haworth A; Delahunt B; Oldmeadow C; Attia J
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(4):693-702. PubMed ID: 32092343
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
